Recombinant Cynomolgus/Rhesus Macaque CD38 Protein, CF

Catalog #: 9834-AC Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
9834-AC-050

R&D Systems Recombinant Proteins and Enzymes

1 Image

Product Details

Reviews

Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Cynomolgus/Rhesus Macaque CD38 Protein, CF Summary

Product Specifications

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

Activity

Measured by its ability to convert the substrate nicotinamide guanine dinucleotide (NGD⁺) to cyclic GDP-ribose. Graeff, R.M. et al. (1994) J. Biol. Chem. 269:30260. The specific activity is >2,900 pmol/min/μg, as measured under the described conditions.

Source

Human embryonic kidney cell, HEK293-derived cynomolgus monkey CD38 protein
Leu44-Ile301, with a C-terminal 6-His tag

Accession #

Q5VAN0

N-terminal Sequence
Analysis

Leu44

Predicted Molecular Mass

31 kDa

SDS-PAGE

36-44 kDa, reducing conditions

Product Datasheets

9834-AC

Product Datasheet

COA

SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

9834-AC

Formulation	Supplied as a 0.2 μm filtered solution in MES and NaCl.
Shipping	The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 6 months from date of receipt, -20 to -70 °C as supplied. 3 months, -20 to -70 °C under sterile conditions after opening.

Assay Procedure

Materials

Assay Buffer: 50 mM MES, pH 6.5
Recombinant (cynoCD38) (Catalog # 9834-AC)
Substrate: Nicotinamide guanine dinucleotide sodium salt (NGD⁺) (Sigma, Catalog # N5131), 10 mM stock in deionized water
F16 Black Maxisorp Plate (Nunc, Catalog # 475515)
Fluorescent Plate Reader (Model: SpectraMax Gemini EM by Molecular Devices) or equivalent

Dilute rcynoCD38 to 2 ng/µL in Assay Buffer.
Dilute Substrate to 400 µM in Assay Buffer.
Load in plate 50 µL of 2 ng/µL rcynoCD38, and start the reaction by adding 50 µL of 400 µM Substrate. Include a Substrate Blank containing 50 µL Assay Buffer and 50 µL of 400 µM Substrate.
Read at excitation and emission wavelengths of 300 nm and 410 nm (top read), respectively, in kinetic mode of 5 minutes.
Calculate specific activity:

Specific Activity (pmol/min/µg) =	Adjusted V_max* (RFU/min) x Conversion Factor** (pmol/RFU)
	amount of enzyme (µg)

*Adjusted for Substrate Blank.
**Derived using calibration standard cyclic GDP ribose (cGDPR).

Per Well:

rcynoCD38: 0.1 µg
Substrate: 200 µM

Reconstitution Calculator

Background: CD38

CD38, also known as ADP‑ribosyl cyclase, converts NAD(P)⁺ into three separate products with calcium mobilizing ability: cyclic ADP-ribose, NAADP⁺, and ADP‑ribose (1). CD38 is a Type II transmembrane glycoprotein composed of an intracellular domain, a single transmembrane helix domain, and a large extracellular domain that contains the catalytic site (2). Within the extracellular domain, cynoCD38 shares 93% amino acid sequence identity with human CD38. CD38 is expressed in B and T lymphocytes, osteoclasts, and in cardiac, pancreatic, liver and kidney cells (3, 4). Through its production of cyclic ADP‑ribose, CD38 modulates calcium‑mediated signal transduction in many types of cells (5, 6). CD38 is also reported to bind as a receptor to trigger signaling cascades (7, 8). Through both mechanisms, CD38 influences proliferation and trafficking (8, 9). CD38 is used as a marker for poor prognosis in chronic lymphocytic leukemia and multiple myeloma and is an attractive cancer immunotherapy drug target (8-11).

References

Schuber, F. and F.E. Lund (2004) Curr. Mol. Med. 4:249.
Liu, Q. et al. (2005) Structure. 13:1331.
Jackson, D.G. and J.I. Bell (1990) J. Immunol. 144:2811.
Sun, L. et al. (1999) J. Cell Biol. 146:1161.
Partida-Sanchez, S. et al. (2001) Nature Med. 7:1209.
Kato, I. et al. (1995) J. Biol. Chem. 270:30045.
Deaglio, S. (2000) Chem. Immunol. 75:99.
Chillemi, A. et al. (2013) Mol. Med. 19:99.
Vaisitti, T. et al. (2015) Leukemia. 29:356.
Atanackovic, D. et al. (2016) Oncoimmunology. 5:e1217374.
Tai, Y-T. et al. (2017) Oncotarget. 8:112166.

Long Name

Cluster of Differentiation 38

Entrez Gene IDs

952 (Human); 12494 (Mouse); 25668 (Rat); 102126394 (Cynomolgus Monkey)

Alternate Names

2'-phospho-ADP-ribosyl cyclase; 2'-phospho-ADP-ribosyl cyclase/2'-phospho-cyclic-ADP-ribose transferase (EC:2.4.99.20); 2'-phospho-cyclic-ADP-ribose transferase; ADPRC 1; ADPRC1; ADP-ribosyl cyclase 1; ADP-ribosyl Cyclase; ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1; ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase; cADPr hydrolase 1; CD_antigen: CD38; CD38 antigen (p45); CD38 antigen; CD38 molecule; CD38; cluster of differentiation 38; Cyclic ADP-ribose hydrolase 1; Cyclic ADP-ribose Hydrolase; EC 2.4.99.20; EC 3.2.2.6; EC:3.2.2.6; NAD(+) nucleosidase; T10